Torrent Pharmaceuticals strengthens diabetes care portfolio with acquisition of anti-diabetes brands

Torrent Pharmaceuticals Limited, a leader in the global pharmaceutical industry, has furthered its diabetes care portfolio with a high-profile acquisition of anti-diabetes brands from Boehringer Ingelheim International GmbH. This strategic move cements its position as a key player in the Indian diabetes market.

The acquisition includes three prominent anti-diabetes brands—Cospiaq, Cospiaq Met, and Xilingio—featuring empagliflozin diabetes treatment. These drugs are part of the oral anti-diabetic category, addressing glycemic control in adults with type 2 diabetes. The deal, expected to be completed by March 2025, reflects Torrent Pharmaceuticals Limited’s commitment to advancing its diabetes care portfolio to meet growing patient needs.

The Boehringer Ingelheim Acquisition: A Growth Catalyst

Torrent Pharmaceuticals Limited has a history of collaboration with Boehringer Ingelheim in the Indian diabetes market, marketing these anti-diabetes brands since 2022 under a co-marketing agreement. By transitioning from co-marketing to ownership, Torrent enhances its ability to deliver innovative empagliflozin diabetes treatments to patients nationwide.

The diabetes care portfolio gains significance as India faces a surge in diabetes cases. With the second-largest diabetes patient base globally, India had an estimated 74.2 million diabetic adults in 2021, expected to rise to 125 million by 2045. This growth underscores the importance of Torrent Pharmaceuticals Limited’s role in providing effective oral anti-diabetic solutions.

Empagliflozin Diabetes Treatment: A Booming Market

Empagliflozin, a sodium glucose co-transporter-2 (SGLT-2) inhibitor, is a cornerstone of the acquired brands. The SGLT-2 inhibitor market, valued at INR 3,235 crore, is growing at an extraordinary rate of 25% CAGR, far outpacing other segments in the Indian diabetes market. The overarching diabetes market, worth INR 19,912 crore, has also demonstrated steady growth, with a 7.7% CAGR over the past four years.

Director Aman Mehta emphasized the company’s commitment to expanding its diabetes care portfolio, stating that the Boehringer Ingelheim acquisition aligns with Torrent’s focus on improving accessibility and enhancing its oral anti-diabetic offerings.

Strength in Chronic Therapy Areas

Torrent Pharmaceuticals Limited, the flagship of the Torrent Group, is already a dominant force in chronic therapy areas, including cardiovascular, central nervous system, and diabetes. The company generates over INR 10,700 crore in annual revenue and ranks seventh in the Indian pharmaceutical market. Its global presence spans over 50 countries, positioning it as a leader in the chronic therapy space.

The Boehringer Ingelheim acquisition also bolsters Torrent Pharmaceuticals Limited’s innovation pipeline. With eight manufacturing facilities and robust R&D infrastructure employing more than 750 scientists, the company is well-equipped to drive growth in chronic therapy areas and deliver high-impact treatments like empagliflozin diabetes solutions.

The Future of India’s Diabetes Care Portfolio

The growing Indian diabetes market presents a critical opportunity for Torrent Pharmaceuticals Limited to address an escalating public health crisis. With its strengthened diabetes care portfolio and control over top-tier anti-diabetes brands, Torrent is set to become a pivotal player in offering innovative, accessible oral anti-diabetic treatments to India’s burgeoning diabetes patient base.